Metastatic Malignant Neoplasm to the Leptomeninges Terminated Phase 2 / 3 Trials for Omburtamab I-131 (DB17124)

Also known as: Leptomeningeal Metastasis / Neoplastic Meningitis / Leptomeningeal Metastases / Metastatic Malignant Neoplasm in the Leptomeninges / Leptomeningeal Disease (LMD) / Leptomeningeal Disease / Lymphomatous meningitis / Leptomeningeal Carcinomatosis / Metastatic malignant neoplasm to leptomeninges (disorder) / Lymphomatous meningitis (disorder) / Malignant meningitis (disorder) / Leptomeningeal Neoplasms / Meningeal dissemination / Metastases to meninges / Meningeal Carcinomatosis

IndicationStatusPhase
DBCOND0057483 (Metastatic Malignant Neoplasm to the Leptomeninges)Terminated2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03275402131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal MetastasesTreatment